Since Bristol–Myers Squibb released deucravacitinib, the world’s first oral TYK2 inhibitor for psoriasis, many ‘big pharms’ have taken notice of a target that was once thought to be ‘un-druggable’! This evidence concerns the gene TYK2 and psoriasis.